THE INTRATUMORAL IMMUNOTHERAPY COMPANY Trademark

Trademark Overview

On Wednesday, January 27, 2021, a trademark application was filed for THE INTRATUMORAL IMMUNOTHERAPY COMPANY with the United States Patent and Trademark Office. The USPTO has given the THE INTRATUMORAL IMMUNOTHERAPY COMPANY trademark a serial number of 90491212. The federal status of this trademark filing is ABANDONED - FAILURE TO RESPOND OR LATE RESPONSE as of Wednesday, August 31, 2022. This trademark is owned by Syncromune, Inc.. The THE INTRATUMORAL IMMUNOTHERAPY COMPANY trademark is filed in the Computer & Software Services & Scientific Services category with the following description:

Research and development in the pharmaceutical and biotechnology fields
the intratumoral immunotherapy company

General Information

Serial Number90491212
Word MarkTHE INTRATUMORAL IMMUNOTHERAPY COMPANY
Filing DateWednesday, January 27, 2021
Status602 - ABANDONED - FAILURE TO RESPOND OR LATE RESPONSE
Status DateWednesday, August 31, 2022
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateNOT AVAILABLE

Trademark Statements

Goods and ServicesResearch and development in the pharmaceutical and biotechnology fields

Classification Information

International Class042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software.
US Class Codes100, 101
Class Status Code6 - Active
Class Status DateWednesday, April 28, 2021
Primary Code042
First Use Anywhere DateSunday, November 1, 2020
First Use In Commerce DateSunday, November 1, 2020

Trademark Owner History

Party NameSyncromune, Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressFort Lauderdale, FL 33339

Trademark Events

Event DateEvent Description
Wednesday, August 31, 2022ABANDONMENT NOTICE E-MAILED - FAILURE TO RESPOND
Wednesday, August 31, 2022ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE
Thursday, February 17, 2022NOTIFICATION OF NON-FINAL ACTION E-MAILED
Thursday, February 17, 2022NON-FINAL ACTION E-MAILED
Thursday, February 17, 2022NON-FINAL ACTION WRITTEN
Tuesday, February 15, 2022TEAS/EMAIL CORRESPONDENCE ENTERED
Tuesday, February 15, 2022CORRESPONDENCE RECEIVED IN LAW OFFICE
Tuesday, February 15, 2022TEAS RESPONSE TO OFFICE ACTION RECEIVED
Tuesday, February 1, 2022ASSIGNED TO EXAMINER
Saturday, January 29, 2022APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Saturday, January 29, 2022TEAS CHANGE OF CORRESPONDENCE RECEIVED
Saturday, January 29, 2022ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Saturday, January 29, 2022TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Saturday, January 29, 2022TEAS CHANGE OF OWNER ADDRESS RECEIVED
Tuesday, August 17, 2021NOTIFICATION OF NON-FINAL ACTION E-MAILED
Tuesday, August 17, 2021NON-FINAL ACTION E-MAILED
Tuesday, August 17, 2021NON-FINAL ACTION WRITTEN
Monday, August 16, 2021ASSIGNED TO EXAMINER
Wednesday, April 28, 2021NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM
Saturday, January 30, 2021NEW APPLICATION ENTERED IN TRAM

Related Keywords

company immunotherapy intratumoral fields biotechnology pharmaceutical development research